Knight Therapeutics' (KHTRF) CEO Jonathan Ross Goodman on Q4 2019 Results - Earnings Call Transcript

Knight Therapeutics Inc. (OTCPK:KHTRF) Q4 2019 Earnings Conference Call March 30, 2020 5:30 PM ET

Company Participants

Jonathan Ross Goodman – Chief Executive Officer
Samira Sakhia – President
Amal Khouri – Vice President-Business Development
Arvind Utchanah – Chief Financial Officer

Conference Call Participants

David Martin – Bloom Burton
Endri Leno – National Bank
Justin Keywood – Stifel

Operator

Good afternoon, ladies and gentlemen, my name is Robert and I will be your operator today. Welcome to the Knight Therapeutics Inc. 2019 Fourth Quarter Financial Results Conference Call.

Before turning the call over to Jonathan Ross Goodman, CEO of Knight, listeners are reminded that portions of today's discussion may, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements.

The company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared by cautions that these assumptions regarding the future events, many of which are beyond the control of the company and its subsidiaries, may ultimately prove to be incorrect. The company disclaims any intentions or obligation to update or revise any forward-looking statements, whether as a result of new information, future events except any required by law.

We would also like to remind you questions during today's call will be taken from analysts only. Should there be any further questions, please contact Knight's Investor Relations department via e-mail to [e-mail] or via phone at 514-678-8930.

I would like to remind everyone that this call is being recorded today, March 30, 2020. I would now like to turn the meeting over to your host for today's call, Jonathan Ross Goodman. Please go ahead, Mr. Goodman.

Jonathan Ross Goodman

Thank you, Robert. Good afternoon, everyone and welcome to Knight Therapeutics fourth quarter 2019 conference